These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 25673130)

  • 1. Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study.
    Moccia M; Lanzillo R; Costabile T; Russo C; Carotenuto A; Sasso G; Postiglione E; De Luca Picione C; Vastola M; Maniscalco GT; Palladino R; Brescia Morra V
    J Neurol; 2015; 262(4):961-7. PubMed ID: 25673130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uric acid: a potential biomarker of multiple sclerosis and of its disability.
    Moccia M; Lanzillo R; Palladino R; Russo C; Carotenuto A; Massarelli M; Vacca G; Vacchiano V; Nardone A; Triassi M; Morra VB
    Clin Chem Lab Med; 2015 Apr; 53(5):753-9. PubMed ID: 25241733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A one-year follow-up study of the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) in relapsing-remitting multiple sclerosis: an appraisal of comparative longitudinal sensitivity.
    López-Góngora M; Querol L; Escartín A
    BMC Neurol; 2015 Mar; 15():40. PubMed ID: 25886168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression.
    Moccia M; Lanzillo R; Palladino R; Chang KC; Costabile T; Russo C; De Rosa A; Carotenuto A; Saccà F; Maniscalco GT; Brescia Morra V
    Mult Scler; 2016 Apr; 22(5):659-67. PubMed ID: 26362896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis.
    Papadopoulou A; Müller-Lenke N; Naegelin Y; Kalt G; Bendfeldt K; Kuster P; Stoecklin M; Gass A; Sprenger T; Radue EW; Kappos L; Penner IK
    Mult Scler; 2013 Sep; 19(10):1290-6. PubMed ID: 23459568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
    Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
    JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum uric acid level in patients with relapsing-remitting multiple sclerosis.
    Ashtari F; Bahar M; Aghaei M; Zahed A
    J Clin Neurosci; 2013 May; 20(5):676-8. PubMed ID: 23528410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
    Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cortical pathology in multiple sclerosis patients with epilepsy: a 3 year longitudinal study.
    Calabrese M; Grossi P; Favaretto A; Romualdi C; Atzori M; Rinaldi F; Perini P; Saladini M; Gallo P
    J Neurol Neurosurg Psychiatry; 2012 Jan; 83(1):49-54. PubMed ID: 21890577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis.
    Kern KC; Gold SM; Lee B; Montag M; Horsfall J; O'Connor MF; Sicotte NL
    Neuroimage Clin; 2015; 8():440-7. PubMed ID: 26106524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study.
    Brochet B; Deloire MS; Bonnet M; Salort-Campana E; Ouallet JC; Petry KG; Dousset V
    Mult Scler; 2008 Nov; 14(9):1242-9. PubMed ID: 18653737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting the course of relapsing-remitting MS using longitudinal disability curves.
    Achiron A
    J Neurol; 2004 Sep; 251 Suppl 5():v65-v68. PubMed ID: 15549358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment.
    Guerrero AL; Martín-Polo J; Laherrán E; Gutiérrez F; Iglesias F; Tejero MA; Rodríguez-Gallego M; Alcázar C
    Eur J Neurol; 2008 Apr; 15(4):394-7. PubMed ID: 18312403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.
    Moccia M; Palladino R; Carotenuto A; Russo CV; Triassi M; Lanzillo R; Brescia Morra V
    Mult Scler Relat Disord; 2016 Nov; 10():90-96. PubMed ID: 27919507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive impairment differs between primary progressive and relapsing-remitting MS.
    Ruet A; Deloire M; Charré-Morin J; Hamel D; Brochet B
    Neurology; 2013 Apr; 80(16):1501-8. PubMed ID: 23516324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.
    Yadav V; Marracci G; Kim E; Spain R; Cameron M; Overs S; Riddehough A; Li DK; McDougall J; Lovera J; Murchison C; Bourdette D
    Mult Scler Relat Disord; 2016 Sep; 9():80-90. PubMed ID: 27645350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal disability curves for predicting the course of relapsing-remitting multiple sclerosis.
    Achiron A; Barak Y; Rotstein Z
    Mult Scler; 2003 Oct; 9(5):486-91. PubMed ID: 14582775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between symbol digit modalities test and regional cortex thickness in young adults with relapsing-remitting multiple sclerosis.
    Tao Y; XueSong Z; Xiao Y; YueZhi K; Xin W; YanPing T; Lei W; YongPing F
    Clin Neurol Neurosurg; 2021 Aug; 207():106805. PubMed ID: 34280674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.